← 返回前沿论文

优化脐血来源 CAR-T 与 NK 细胞制备的激活与培养条件

英文原题:Optimizing activation and culture conditions for the production of cord blood-derived CAR-T and natural killer cells.

查看英文原题

Optimizing activation and culture conditions for the production of cord blood-derived CAR-T and natural killer cells.

PubMed 2025/09/30(内容时间) Br J Haematol Q2 · IF 3.6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

脐带血(CB)作为嵌合抗原受体(CAR)T/NK 细胞的一种来源正受到关注。

中文摘要

脐带血(CB)正成为嵌合抗原受体(CAR)T/NK细胞的潜在来源。许多研究关注治疗效果,但对于脐带血来源CAR-T/NK细胞生产初期,如何激活和培养T/NK细胞而不使其过度耗竭,尚无定论。已有研究将外周血(PB)CAR-T/NK细胞的活化和培养条件用于脐带血来源CAR-T/NK细胞,但PB和CB淋巴细胞的组成及成熟度不同。因此,本研究旨在优化脐带血来源CAR-T/NK细胞的生产活化和培养条件。我们比较不同剂量的多种细胞因子后发现,以下方案在活化和耗竭之间取得最佳平衡:PB-T细胞先接受CD3/CD28激动剂刺激,随后加入40 U/mL IL-7和40 U/mL IL-15;CB-T细胞加入40 U/mL IL-2、40 U/mL IL-7和40 U/mL IL-15;PB-NK细胞加入40 U/mL IL-2和40 U/mL IL-15;CB-NK细胞加入40 U/mL IL-2和200 U/mL IL-15。杀伤实验确认,这些细胞因子方案可提高抗肿瘤作用。研究结果有助于开发脐带血来源CAR-T/NK细胞疗法,并提示这些疗法具有应用潜力。

展开英文摘要原文

Cord blood (CB) is gaining attention as a source of chimeric antigen receptor (CAR) T/NK cells. Many studies have focused on the therapeutic effects, but the methods of activating and culturing T/NK cells without excessive exhaustion during the initial stages of the production of CB-derived CAR-T/NK cells are yet to be established. The activation and culture conditions developed for peripheral blood (PB) CAR-T/NK cells have been used for CB-CAR-T/NK cells, but there are differences in the composition and maturity of PB and CB lymphocytes. Thus, this study aims to optimize activation and culture conditions for the production of CB-CAR-T/NK cells. We compared different doses of various cytokines and found that the balance between activation and exhaustion was best with stimulation with a CD3/CD28 agonist followed by 40 U/mL interleukin (IL)-7+ 40 U/mL IL-15 for PB-T cells; 40 U/mL IL-2+ 40 U/mL IL-7+ 40 U/mL IL-15 for CB-T cells; 40 U/mL IL-2+ 40 U/mL IL-15 for PB-NK cells; and 40 U/mL IL-2+ 200 U/mL IL-15 for CB-NK cells. Using killing assays, we confirmed that these cytokine protocols improved the anti-tumour effects. These results will be useful for the development of CB-CAR-T/NK-cell therapies and suggest the potential of these modalities.

论文信息

作者
Nakamura N、Liao J、Soda Y、Takahashi M、Kodera H、Kobari Y、Hirai Y、Takaori-Kondo A
单位
Division of Molecular and Medical Genetics, Center for Gene & Cell Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.Japan
期刊
British journal of haematology2025 Nov
原文标识
PubMed 41030086 · DOI 10.1111/bjh.70139